The fitness of SARS-CoV-2 Omicron subvariants was determined in human epithelial and continuous cells of the respiratory and gastrointestinal tracts. Competition experiments over 4 days were performed followed by quantification of variant ratios by reverse transcription-droplet digital PCR. These quantitative data were correlated with whole genome sequencing. In competition experiments of two subvariants, the more recent XBB.1 subvariant outcompeted the BA.1.15 subvariant at early time points in the upper respiratory tract epithelium. No difference in replication was observed between the two subvariants in the lower respiratory tract. Furthermore, XBB.1 predominated over BA.1.15 and JN.1.1 subvariants in the gastrointestinal tract.

中文翻译：

---

通过 RT-ddPCR 和全基因组测序确定呼吸道和胃肠道细胞系中 SARS-CoV-2 Omicron 亚变体的适应性


SARS-CoV-2 Omicron 亚变体的适应性是在呼吸道和胃肠道的人类上皮细胞和连续细胞中确定的。进行为期 4 天的竞争实验，然后通过逆转录-液滴数字 PCR 定量变异比率。这些定量数据与全基因组测序相关。在两个亚变体的竞争实验中，最近的 XBB.1 亚变体在上呼吸道上皮的早期时间点超过了 BA.1.15 亚变体。在下呼吸道的两个亚变体之间未观察到复制差异。此外，XBB.1 在胃肠道中优于 BA.1.15 和 JN.1.1 亚变体。